Birth Control News and Research

RSS

Ninth Circuit rules in favor of ACLJ in multi-million dollar fraud case against Planned Parenthood affiliates

The United States Court of Appeals for the Ninth Circuit has ruled in favor of the American Center for Law and Justice's (ACLJ) client in a multi-million dollar fraud case against Planned Parenthood (PP) affiliates in California. ACLJ attorneys are representing a former employee of the PP affiliate in Los Angeles, who is now a federal whistleblower. A federal district court in California had dismissed the case, but the Ninth Circuit's ruling, dated yesterday, reinstates the lawsuit.

3 Jul 2010

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

Genentech, a member of the Roche Group, announced today that a second large, Phase III, international study showed that the combination of Avastin® (bevacizumab) and chemotherapy, followed by the continued use of Avastin alone, increased the time women with previously untreated ovarian cancer lived without the disease worsening (progression-free survival or PFS, the primary endpoint), compared to chemotherapy alone.

2 Jul 2010

News round up: UniCare will drop health coverage for Virginians; Hawaii concerned about lack of physicians

The Washington Post: "About 3,000 Virginians who have health insurance through UniCare, a private insurer, will lose that coverage Jan. 1, a UniCare spokesman said Monday. Most live in Northern Virginia and get their coverage through the individual market, officials said.

30 Jun 2010

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Merck today announced plans to initiate a Phase II investigational proof-of-concept clinical study to evaluate its oral antifungal agent posaconazole for the treatment of chronic Chagas disease. Chagas disease results from infection with the parasite Trypanosoma cruzi that is spread by biting insects. The disease is estimated to affect approximately eight million people in Latin America, of whom approximately 30-40 percent will develop serious cardiac disease, digestive disease, or both as a result of this infection.

24 Jun 2010

Risk, incidence of VTE differs between races

A new study of 1,960 White-Americans and 368 Black-Americans with objectively diagnosed venous thromboembolism (VTE) showed that, compared to Whites, Blacks had a significantly higher proportion with pulmonary embolism (PE), including idiopathic PE among Black women, and a significantly higher proportion of Blacks with VTE were women (71% vs 61% for Whites) The study is published today in the American Journal of Hematology.

24 Jun 2010

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Ferring Pharmaceuticals Inc. announced today the U.S. commercial availability of LYSTEDA™ (tranexamic acid) tablets, the only non-hormonal and non-surgical therapy indicated specifically for the treatment of women with cyclic heavy menstrual bleeding (HMB). In clinical studies, LYSTEDA significantly reduced menstrual blood loss (MBL) over three and six cycles of use with the reduction seen as early as the first cycle of use.

21 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

Today, Bayer HealthCare Pharmaceuticals Inc. and Bayer Schering Pharma AG sued Teva Pharmaceuticals USA, Inc., Barr Pharmaceuticals LLC, and Barr Laboratories, Inc. in the Northern District of Illinois (Chicago) for false advertising and patent infringement in connection with Teva's generic oral contraceptive, Gianvi™. Teva's product is sold as a generic version of Bayer HealthCare's leading oral contraceptive YAZ®.

16 Jun 2010

DermaGenoma releases CelluliteDX Genetic Test for women

As summer swimsuit season heats up, women around the world will inspect their looks in the mirror. A majority of them will see cellulite - at some point - but a new genetic test may be able to help them avoid cellulite before anyone notices.

10 Jun 2010

First clinical trial among African women to test vaginal ring that prevents HIV transmission

The nonprofit International Partnership for Microbicides today announced the initiation of the first trial among women in Africa testing a vaginal ring containing an antiretroviral drug that could one day be used to prevent HIV transmission during sex. The clinical trial, known as IPM 015, tests the safety and acceptability of an innovative approach that adapts a successful technology from the reproductive health field to give women around the world a tool to protect themselves from HIV infection.

9 Jun 2010

Single semen test for clearance following vasectomy

Having to provide repeated semen samples following a vasectomy could soon be a thing of the past, after 96 per cent of men were given the all-clear based on a single test three months after surgery.

8 Jun 2010

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Genentech, Inc., a wholly owned member of the Roche Group, today announced results from a Phase III study of Avastin (bevacizumab) that showed women with previously untreated advanced ovarian cancer who received Avastin in combination with chemotherapy, followed by the continuation of Avastin alone, had a 39 percent improvement in the likelihood of living longer without the disease worsening (progression-free survival or PFS) compared to chemotherapy alone.

7 Jun 2010

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Merck announced today results from a new non-inferiority trial of an antiemetic regimen containing fosaprepitant dimeglumine administered as a single intravenous (IV) 150-mg dose in combination with a 5-HT3 antagonist and dexamethasone compared with a three-day regimen of aprepitant with a 5-HT3 antagonist and dexamethasone for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving a first cycle of cisplatin-based chemotherapy.

4 Jun 2010

Health law implementation: Insurance, coverage and Medicare payment questions

Kaiser Health News reports that the insurance industry — traditionally a state-regulated industry — is facing new federal scrutiny by four officials in the new Office of Consumer Information and Insurance Oversight. "On this year's to-do list: writing rules to define when premium increases are 'unreasonable,' creating new coverage for people who can't get it because of health conditions and making sure insurers comply with consumer protections. The new director of the office is Jay Angoff, a former Missouri insurance commissioner.

2 Jun 2010

First Edition: June 1, 2010

A number of today's headlines focus on the continuing role of health reform in national political calculations and strategies.

1 Jun 2010

Opinions: Family planning; U.S. food aid

In his latest New York Times column, Nicholas Kristof writes about the "unavailability of birth control in many poor countries," noting some experiences from a recent trip to Africa.

24 May 2010

HTDS Collagenna Skin Care Products enters into exclusive distribution agreement with Medimec

Hard to Treat Diseases Collagenna Skin care Products has entered into an exclusive distribution agreement with the Malaysian company Medimec www.medimec.com.my

21 May 2010

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Results of two Phase II trials evaluating ALIMTA (pemetrexed for injection) in combination with a platinum chemotherapy and radiation for patients with locally advanced non-small cell lung cancer will be presented by Eli Lilly and Company at the 46th Annual Meeting of the American Society of Clinical Oncology in Chicago, Ill., on June 6, 2010.

21 May 2010

Genentech to present new data for targeted cancer medicines at 46th ASCO

Genentech, Inc., a wholly owned member of the Roche Group, today announced that it will present new data for its targeted cancer medicines and the way they may be used in several different cancer types at the 46th Annual Meeting of the American Society of Clinical Oncology (ASCO). Approximately 400 abstracts featuring Genentech and Roche's cancer medicines and investigational agents across 30 cancer types will be presented during the meeting that is taking place June 4 to 8, 2010 in Chicago.

21 May 2010

FDA approves Conceptus' ESS305 Essure procedure for increased bilateral placement rate of 96.9%

Conceptus Inc., developer of the Essure(R) procedure, the first and proven non-surgical permanent birth control method, announced today that the third generation (ESS305) of the Essure procedure has received FDA-approval for an improved bilateral placement rate of 96.9%. Improvement in the hysteroscopic time of 9 minutes is an additional benefit.

19 May 2010

Birth Control News and Research

Ninth Circuit rules in favor of ACLJ in multi-million dollar fraud case against Planned Parenthood affiliates

Genentech's second Phase III ICON7 study of Avastin in ovarian cancer meets primary endpoint

News round up: UniCare will drop health coverage for Virginians; Hawaii concerned about lack of physicians

Merck proposes to initiate Phase II proof-of-concept clinical study of posaconazole for chronic Chagas disease

Risk, incidence of VTE differs between races

Ferring announces availability of LYSTEDA for cyclic heavy menstrual bleeding in U.S.

Advisory panel recommends FDA approve new "morning after" pill

Bayer sues Teva, Barr in connection with oral contraceptive Gianvi

DermaGenoma releases CelluliteDX Genetic Test for women

First clinical trial among African women to test vaginal ring that prevents HIV transmission

Single semen test for clearance following vasectomy

Genentech reports results from Phase III study of Avastin in women with advanced ovarian cancer

Antiemetic-regimen with fosaprepitant injection provides similar protection against CINV as oral EMEND

Health law implementation: Insurance, coverage and Medicare payment questions

First Edition: June 1, 2010

Opinions: Family planning; U.S. food aid

HTDS Collagenna Skin Care Products enters into exclusive distribution agreement with Medimec

Eli Lilly to present results of two Phase II trials evaluating ALIMTA in combination with chemotherapy, radiation

Genentech to present new data for targeted cancer medicines at 46th ASCO

FDA approves Conceptus' ESS305 Essure procedure for increased bilateral placement rate of 96.9%

Advancing Intracellular Delivery with LumiPore®

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Latest News